{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:26:03Z","timestamp":1793316363962,"version":"4.5.0"},"reference-count":28,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-018-0478-8","type":"journal-article","created":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T17:44:44Z","timestamp":1546796684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":258,"title":["Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience"],"prefix":"10.1136","volume":"7","author":[{"given":"Omar","family":"Mamlouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Selamet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tchakarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Lahoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biruh","family":"Workeneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Tayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,6]]},"reference":[{"key":"478_CR1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"478_CR2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"478_CR3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"478_CR4","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018. \nhttps:\/\/doi.org\/10.1200\/JCO.2017.77.6385\n\n.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"478_CR5","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, et al. Pooled analysis safety profile of Nivolumab and Ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35:3815\u201322.","journal-title":"J Clin Oncol"},{"key":"478_CR6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785\u201392.","journal-title":"J Clin Oncol"},{"key":"478_CR7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5:95.","journal-title":"J Immunother Cancer"},{"key":"478_CR8","doi-asserted-by":"publisher","unstructured":"Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76\u201383. \nhttps:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.76\n\n.","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"478_CR9","first-page":"102A","volume":"27","author":"T Jonathan","year":"2016","unstructured":"Jonathan T, Lin MS, Salvatore S, Shoushtari AN, Glezerman I. Membranous Nephropathy Related to the Checkpoint Inhibitor Nivolumab. J Am Soc Nephrol. 2016;27:102A.","journal-title":"J Am Soc Nephrol"},{"key":"478_CR10","unstructured":"Ina Cusnir KS, Yacyshyn E. Granulomatosis with Polyangitis Assosciated with Immune Checkpoint Blockade: Case report and Literature Review. J Rheumatol. 2017:950\u2013A247."},{"key":"478_CR11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361:211\u20132.","journal-title":"N Engl J Med"},{"key":"478_CR12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","volume":"55","author":"RR Brom van den","year":"2016","unstructured":"van den Brom RR, Abdulahad WH, Rutgers A, et al. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford). 2016;55:1143\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"478_CR13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","volume":"40","author":"RA Daanen","year":"2017","unstructured":"Daanen RA, Maas RJH, Koornstra RHT, Steenbergen EJ, van Herpen CML, Willemsen A. Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report. J Immunother. 2017;40:345\u20138.","journal-title":"J Immunother"},{"key":"478_CR14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","volume":"70","author":"A Kitchlu","year":"2017","unstructured":"Kitchlu A, Fingrut W, Avila-Casado C, et al. Nephrotic syndrome with Cancer immunotherapies: a report of 2 cases. Am J Kidney Dis. 2017;70:581\u20135.","journal-title":"Am J Kidney Dis"},{"key":"478_CR15","doi-asserted-by":"crossref","unstructured":"Kishi S, Minato M, Saijo A, et al. A case of IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med. 2018;57(9):1259-63.","DOI":"10.2169\/internalmedicine.9814-17"},{"key":"478_CR16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","volume":"17","author":"K Jung","year":"2016","unstructured":"Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol. 2016;17:188.","journal-title":"BMC Nephrol"},{"key":"478_CR17","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.","journal-title":"Crit Care"},{"key":"478_CR18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90:638\u201347.","journal-title":"Kidney Int"},{"key":"478_CR19","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18:1899\u2013904.","journal-title":"J Am Soc Nephrol"},{"key":"478_CR20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ndt\/gfw470","volume":"33","author":"S Nochaiwong","year":"2018","unstructured":"Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33:331\u201342.","journal-title":"Nephrol Dial Transplant"},{"key":"478_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45:160\u20139.","journal-title":"Am J Nephrol"},{"key":"478_CR22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis with Programmed Cell Death 1 inhibitor therapy in lung Cancer patients. Am J Kidney Dis. 2016;68:287\u201391.","journal-title":"Am J Kidney Dis"},{"key":"478_CR23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9:411\u20137.","journal-title":"Clin Kidney J"},{"key":"478_CR24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342.","journal-title":"Immunol Rev"},{"key":"478_CR25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"478_CR26","first-page":"1164","volume":"378","author":"JW Cohen Tervaert","year":"2018","unstructured":"Cohen Tervaert JW, Ye C, Yacyshyn E. Adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:1164\u20135.","journal-title":"N Engl J Med"},{"key":"478_CR27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"478_CR28","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353.","journal-title":"JAMA Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0478-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:51Z","timestamp":1601041491000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0478-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0478-8","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,6]]},"article-number":"2"}}